placebo combined with chemotherapy

DRUG2 trials

Sponsors

Xijing Hospital, Shandong New Time Pharmaceutical Co., LTD

Conditions

Cancer of Unknown Primary SiteImmune Checkpoint InhibitorsStomach Neoplasms

Phase 2

Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

Active, not recruitingNCT06576921

Xijing HospitalImmune Checkpoint Inhibitors, Stomach Neoplasms

Start: 2024-11-15End: 2026-09-30Target: 116Updated: 2026-09-10

A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)

RecruitingNCT07761429

Shandong New Time Pharmaceutical Co., LTDCancer of Unknown Primary Site

Start: 2026-07-08End: 2028-04-01Target: 402Updated: 2026-08-12

Related Papers

Neoadjuvant serplulimab plus nab-paclitaxel and SOX in locally advanced gastric or gastroesophageal junction adenocarcinoma: An interim analysis of a multicenter, randomized, double-blind, phase II trial.

Journal of Clinical Oncology2026-05-28